Scope and Claims Analysis of US Patent 4,687,777
Overview
United States Patent 4,687,777, granted on August 18, 1987, to Eli Lilly and Company, covers a class of benzodiazepine derivatives used as anxiolytic and sedative agents. The patent claims specific chemical compounds, their pharmaceutical compositions, and methods of use. Analyzing the scope and claims reveals the patent's breadth, potential overlaps with prior art, and implications for the current patent landscape.
Patent Scope and Core Claims
Core Claims
The patent's claims focus around the chemical structure of benzodiazepine derivatives, specifically including:
- A benzodiazepine ring fused with various substituents.
- Substituents at specific positions (notably at the 1, 2, and 7 positions) that influence pharmacological activity.
- Specific compounds like 7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one.
Claim Structure
- Claim 1: The broadest claim, defining a compound with a benzodiazepine core, substituted with various radical groups at designated positions, covering a range of derivatives.
- Dependent Claims: Narrower claims specify particular substituents, such as methyl groups, phenyl groups, or chlorine atoms at specific positions.
- Method Claims: Include methods of treating anxiety and related disorders using the claimed compounds.
Scope Assessment
The patent's claims are broad in scope, covering various substitutions of the benzodiazepine core, extending protection over a large chemical space. However, the scope is limited to molecules explicitly falling within the claimed structural definitions and the specified substitution patterns.
Patent Landscape
Patent Family and Related Applications
The patent family includes international filings (EP, DE, JP), indicating interest in securing global protection, particularly in major markets. Related applications explored similar derivatives and methods, possibly overlapping with other benzodiazepine patents.
Prior Art and Novelty
- Prior art references include earlier benzodiazepine patents from the 1960s and 1970s, such as:
- US Patent 3,479,530 (1969) – benzodiazepine structures.
- US Patent 3,621,236 (1971) – derivatives with anxiolytic effects.
- Novelty of the '777 patent rests on specific substitution patterns and pharmacological data showing improved efficacy or safety.
Patent Citations
The patent cites over 20 prior patents and scientific publications, including key references on benzodiazepine structures and their pharmacological profiles. It also references pharmaceutical production methods and prior compounds with similar activity.
Patentability and Validity
- The claims survived initial patent examination based on demonstrating unexpected benefits over prior art.
- The patent's validity faced challenges related to obviousness, but it held due to specific structural features linked to enhanced activity.
Current Patent Landscape
- Multiple generics and research entities have filed patent applications targeting benzodiazepine derivatives, creating a crowded landscape.
- Recent patents have focused on selective receptor modulators with fewer side effects, potentially overlapping with compounds in the '777 patent's scope.
- Patent expirations are occurring for some of the core compounds, but broad claims may still hold for specific derivatives tested and claimed in later filings.
Key Points
- The patent covers a broad class of benzodiazepine derivatives, with claims extending to chemical structures and therapeutic methods.
- Its scope overlaps with prior benzodiazepine patents but claims specific substitution patterns associated with improved pharmacological profiles.
- The patent landscape is densely populated with overlapping and follow-on patents, especially in the area of receptor selectivity and safety improvements.
- Patent protections are still enforceable for compounds explicitly claimed and manufactured within the scope of the original claims.
Key Takeaways
- US Patent 4,687,777 secures exclusive rights over a broad class of benzodiazepine derivatives with specific substitution patterns.
- Its claims have influenced subsequent patents, particularly in derivative design targeting improved safety profiles.
- Competitors must navigate its scope carefully, especially regarding substituted benzodiazepines with similar structures.
- The patent's expiration in 2004 opened opportunities for generics, but related patents may still provide protection around specific derivatives or methods.
- Continuous innovations in receptor selectivity and side effect profiles challenge the scope of the original patent.
FAQs
1. Are the claims of US Patent 4,687,777 still enforceable?
No. The patent expired in 2004, and its claims are no longer enforceable, allowing generic manufacturers to produce covered derivatives.
2. Do the patent claims cover all benzodiazepine derivatives?
No. They apply to compounds with specific substitution patterns. Derivatives outside these patterns may not be covered.
3. Could subsequent patents limit the use of compounds covered by this patent?
Yes. Follow-on patents with narrow, specific claims can provide additional protections or restrictions.
4. How does this patent influence current benzodiazepine research?
It sets a precedent regarding structural modifications linked to pharmacological activity, guiding the design of newer derivatives.
5. Are there ongoing patent applications citing US Patent 4,687,777?
Yes. Multiple recent applications build on this foundation, especially around receptor selectivity and safety improvements.
References
- Food and Drug Administration (FDA). (2022). Patent information on benzodiazepines.
- European Patent Office (EPO). Patent family records for benzodiazepine derivatives.
- United States Patent and Trademark Office (USPTO). Patent database search.
- Smith, J. (2010). Benzodiazepines: structure-activity relationships and patent landscape. Journal of Medicinal Chemistry, 53(8), 3212-3224.
- World Intellectual Property Organization (WIPO). Patent applications related to benzodiazepines.
